Abstract
The antiviral activity of compound (5) was demonstrated by a reduction in influenza A viral infectivity of 2.0 log10 for H3N2 (99% inactivation) and 1.9 log10 for H1N1 (98.7% inactivation) at a dose of 0.4 mg/embryo. The compound demonstrated no noticeable embryotoxicity at the maximum tested dose of 0.4 mg/embryo, while the LD50 was not reached within the investigated concentration range. Notably, its therapeutic index outperforms rimantadine and oseltamivir. Furthermore, a scalable 8-stage laboratory production protocol was successfully validated. These findings position compound (5) as a highly promising, low-toxicity domestic prototype for the development of innovative, multi-targeted anti-influenza pharmaceutical drugs.